Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Transition Bio Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.transitionbio.com/...
Year Founded: 2020
Status: Private
BioCentury | Jan 6, 2024
Discovery & Translation
Immunotherapy, hold the intestinal inflammation; plus Chugai and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 3, 2022
Deals
June 2 Quick Takes: BMS, Immatics expand partnership to allogeneic T cells
Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more
BioCentury | Oct 13, 2021
Management Tracks
Harler joins IGM as president of autoimmunity and inflammation business
Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more
BioCentury | Dec 11, 2020
Emerging Company Profile
Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology
Emerging Company Profile: dissecting normal and pathogenic biomolecular condensate biology to enable drug development
BioCentury | Dec 1, 2020
Product Development
Nov. 30 Quick Takes: Grail piloting blood test in U.K.; plus Rhythm, Kadmon, venture rounds for Adrenomed, Xbiome, Transition
Grail piloting cancer blood test with NHS EnglandGrail Inc. announced a pilot program with NHS England using the company's Galleri blood test to monitor 140,000 asymptomatic participants aged 50
Items per page:
1 - 5 of 5